Peristaltic pump tubing in single-use biopharmaceutical manufacturing is subjected to repeated compression cycles, backpressure spikes, and terminal sterilization before process fluid contact. Compounds based on Kraton™ MD1653 styrene-ethylene/butylene-styrene (SEBS) are formulated without ortho-phthalate plasticizers; this reduces migration risk into aqueous process streams. Pellet handling on high-shear compounding lines begins with moisture control. When ambient relative humidity exceeds 60%, pellets are dried at 70°C for 2 h to prevent splay defects in downstream injection molding. An oil-free compound typically incorporates polypropylene random copolymer at 10-25 wt% to elevate hardness and reduce surface tack without introducing extractable oils. Compounding uses a corotating twin-screw extruder with 40:1 L/D or 44:1 L/D. The screw configuration includes an atmospheric vent after the first mixing zone and a vacuum vent before the strand die. Die melt temperature is maintained between 190°C and 220°C. Excursions above 230°C increase gel speck formation; temperatures below 185°C produce poor polypropylene dispersion and visible domains at the strand surface. The pellet is then tube-extruded through a barrier screw single-screw line with a compression ratio of 2.5:1 to 3.0:1. Lower compression ratios create annular weld lines in thin-wall tubing. Peristaltic tubing is rotated 90° between extrusion and cutting to avoid preferential thinning at the weld line. If the tubing is used in enteral feeding sets, connector compatibility is evaluated under ISO 80369-3:2016. Finished tubing is tested under ISO 10993-5:2009 for cytotoxicity and ISO 10993-10:2010 for skin sensitization when patient contact is intended. Pump life is evaluated by compression set under ASTM D395-18 Method B at 70°C because room-temperature data do not predict dynamic occlusion performance. Spallation resistance is characterized gravimetrically after pump cycling; published data for specific MD1653 pump constructions are limited, so qualification is completed on the finished tube assembly.

How Does MD1653 Alter Melt Viscosity and Blending Index in Polypropylene-Rich Compounds?

Viscosity mismatch between polymeric phases governs the morphology of SEBS/PP blends. When MD1653 is compounded with isotactic polypropylene at PP loadings above 25 wt%, the continuous phase can invert if the PP melt flow rate is not matched; this produces hard, brittle strands and erratic pellet quality. Production compounding records for oil-free blends use PP grades with melt flow rate of 10-25 g/10 min under ISO 1133-1:2022 conditions (230°C, 2.16 kg). At these viscosities, SEBS-rich continuous morphology is targeted at MD1653/PP ratios of 70/30 to 60/40. At 50/50, morphology becomes co-continuous and processing stability narrows. Twin-screw extrusion with a 44:1 L/D corotating intermeshing screw is configured with two kneading blocks after the main feed, followed by a left-handed element to create backpressure. Specific energy input is monitored between 0.20 kWh/kg and 0.30 kWh/kg; lower values leave PP agglomerates, higher values promote shear-induced chain scission. Die temperature is held at 200-210°C. Strand pelletizing uses a water bath at 35-45°C. Higher bath temperature softens the strand and deforms pellets; colder water induces internal voids. A property cliff-edge is observed at PP additions beyond 35 wt%; hardness increases disproportionately and tensile elongation at break falls below acceptance limits for flexible medical components when tested per ASTM D638-14. Oil-free compounds targeting hardness below 60 Shore A therefore keep PP addition below 25 wt%. Melt viscosity of the neat MD1653 phase is high; a small amount of a medium-molecular-weight PP homopolymer at 5-10 wt% may improve mold filling, but this addition shifts compression set and must be validated against ASTM D395-18 Method B at 70°C.

In pharmaceutical closure and syringe gasket molding, the polymer must withstand autoclave conditions while releasing minimal organic extractables into aqueous drug formulations. MD1653-based closure compounds are formulated without natural rubber proteins and without sulfur-vulcanization residuals. Injection molding is performed on reciprocating screw machines with barrel zones set at 180°C, 190°C, 200°C, and nozzle at 210°C; mold surfaces are held at 25-40°C to prevent flash and surface tack. Cold runner systems are preferred because hot runners increase residence time and can generate yellowing bodies. For parenteral closures, molded parts are qualified under ISO 8871-1:2003; key indicators include hardness, penetration, and fragmentation. No secondary crosslinking is required for many closure designs, although electron-beam crosslinking at 60-80 kGy is used when compression set below 20% at 70°C is specified. Oil-free formulations are used where low extractable profiles are critical; addition of white mineral oil above 10 phr reduces hardness but increases the extractable load and the risk of clouding in the drug solution. Steam sterilization at 121°C for 30 min shifts hardness and dimensions slightly; qualification batches are therefore conditioned according to the finished-device sterilization protocol before final dimensional inspection. The material is not suitable for closure designs that require high oxygen barrier because SEBS is a nonpolar hydrocarbon and exhibits moderate oxygen transmission; barrier is supplied by the package architecture rather than the closure compound.

When Gamma Sterilization Doses Exceed 25 kGy, Property Retention Requires Accelerated Aging Review

Gamma irradiation of SEBS-based compounds generates free radicals that can recombine, chain-scission, or oxidize depending on dose rate, dose uniformity, and antioxidant package. For MD1653-based medical devices sterilized to ISO 11137-2:2013, a minimum dose of 25 kGy is common; many terminal sterilization protocols operate between 25 kGy and 40 kGy. At these doses, tensile strength retention is typically within specification when the compound contains a hindered phenolic primary antioxidant and a phosphite secondary antioxidant. A processing boundary emerges above 50 kGy. Published data for MD1653-specific formulations exposed above 50 kGy are limited; discoloration index and elongation-at-break retention must be measured on molded plaques per ASTM D638-14 after accelerated aging according to ASTM F1980-16. Because oxidative degradation is diffusion-limited, thick sections may retain degradation products after irradiation; ventilated storage for 48 h at ambient temperature is applied before packaging. Amine-based stabilizers are avoided in gamma-stable compounds because aromatic amines contribute to color shifts; antioxidant selection is therefore restricted to phenolic and phosphite chemistries. Polypropylene-rich MD1653 blends show more pronounced post-radiation embrittlement than oil-free SEBS-rich grades; irradiation qualification therefore uses the exact production ratio of PP and any color masterbatch.

Chill-Roll Cast Film, Seal Strength, and IV Bag Overwrap Structures

Cast film lines running MD1653-based formulations require precise control of chill-roll temperature to manage tack and heat-seal response. Film compounds based on MD1653 are often blended with 10-20 wt% low-density polyethylene or polypropylene to reduce surface drag and improve sealing. Monolayer cast film is produced on a 30:1 L/D single-screw extruder with a barrier screw and a flex-lip die gap of 0.5-1.0 mm; melt temperature at the die lip is held between 200°C and 230°C. The primary chill roll is supplied with water at 20-35°C; temperatures below 15°C create haze and surface microcracks, while temperatures above 40°C cause blocking on the winder. Lower roll pressure and reduced secondary winding tension lower blocking tendency. Heat-seal performance is measured under ASTM F88/F88M-21 with a 25.4 mm wide specimen; seal strength depends on sealing temperature, dwell time, and the molecular compatibility of the sealant layers. Because MD1653 is olefinic, sealing to polyethylene or polypropylene surfaces occurs by fusion; sealing to polyester or nylon requires an adhesive tie layer. The film is not inherently an oxygen barrier; in overwrap construction, barrier performance is provided by a coextruded EVOH core with tie layers. For IV bag overwrap, the sealant layer is tested for seal integrity after sterilization and accelerated aging, not merely for initial peel force.

Two-shot injection molding of soft-touch grip surfaces onto reusable surgical instruments or device housings uses the olefinic affinity of MD1653 to bond to polypropylene substrates. The substrate is molded first; the MD1653-based soft-touch layer is overmolded at barrel temperatures of 190-215°C and mold temperatures of 30-50°C. Interface temperature is the dominant variable; if the molded substrate drops below the SEBS softening point before the second shot arrives, a cold interface results and peel strength falls steeply. Polycarbonate or ABS substrates do not form a reliable fusion bond with MD1653 without a primer or mechanical interlock, so those designs are not recommended without a tie layer. The soft-touch compound may be oil-extended to achieve hardness below 40 Shore A; however, oil bloom on high-gloss substrates can emerge after thermal cycling. Surface friction is measured under ASTM D1894-14; coefficient of friction values below 0.6 are typically targeted, but the value is surface-texture dependent. Durability is assessed via repeated wiping with quaternary ammonium disinfectants and 70% isopropanol; swelling or tack after 100 cycles indicates inadequate midblock compatibility with the selected oil. Because MD1653 absorbs some surface oil during molding, parts are not post-cured; they are packed only after dimensional convergence at room temperature.